We all have one: a junk drawer that we stuff full of all our random — and often useless — items that we can’t throw away. However, once in a while, there’s something in that drawer that ends up being more useful than we initially thought. According to a new study, this is also true for the human body.
An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a Phase I clinical trial has shown.
The Global Neurodegeneration Proteomics Consortium (GNPC) has published a series of research papers detailing their efforts to identify patterns in neurodegenerative disease.
Tiny fat bubbles carrying gene therapy have successfully repaired DNA in the lungs and liver of animals with alpha-1 antitrypsin deficiency—a promising leap toward treating humans with this rare inherited disease.
Certification Advances Global Access to Comprehensive Genetic Testing and Precision Medicine Solutions in Europe
A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models, according to a study reported in Science Translational Medicine.
SAN FRANCISCO, July 16, 2025 /PRNewswire/ — Piccolo Medical, Inc. (Piccolo), a leading innovator in vascular access technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next-generation SmartPICC® Stylet and PM2+™ System. This significant achievement marks a major leap forward in safe, efficient, and cost-effective peripherally inserted central catheter (PICC) placement, offering enhanced benefits for both patients and healthcare providers.
CHARLOTTESVILLE, Va., July 16, 2025 /PRNewswire/ — RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or catheter placement.
Genetic changes can signal evidence of disease, but pinpointing which genes and what’s changed can be difficult.
Recently, researchers from Prof. Eran Segal’s laboratory at the Weizmann Institute of Science have harnessed artificial intelligence to create a personalized “digital twin” that allows them to detect a risk of developing diseases, initiate preventive treatment and even run simulations to predict which treatment will be most effective.